TABLE 1

Detailed Patient Characteristics

Patient no.	Sex	Age (y)	Metastatic sites	Disease type	Prior therapy	Somatic RET mutation
1	F	57	LN, lung, liver	Sporadic	Surgery	Unknown
2	F	59	LN, liver	Sporadic	Surgery, CTx, TACE	Negative
3	M	41	LN, bone	Sporadic	Surgery, CTx	Unknown
4	M	50	LN, lung	Sporadic	Surgery	Unknown
5	F	20	LN, lung, liver	Sporadic	Surgery	Negative
6	M	57	LN, lung, liver, bone	Hereditary	Surgery, TACE	—
7	M	40	LN, lung	Sporadic	Surgery, CTx	Unknown
8	M	40	LN, liver, bone	Sporadic	Surgery	Negative
9	F	35	LN, lung	Sporadic	Surgery	Negative
10	M	59	LN, lung	Sporadic	Surgery	Unknown
11	M	30	LN	Sporadic	Surgery, RTx	Negative
12	M	47	LN, liver, bone, soft tissue, pancreatic infiltration	Sporadic	Surgery	Unknown
13	M	54	LN, lung, liver	Sporadic	Surgery	Unknown
14	M	78	LN, lung, bone	Sporadic	Surgery	Unknown
15	F	49	LN, liver, bone	Sporadic	Surgery, RTx	Positive
16	F	28	LN, bone	Sporadic	Surgery, radioiodine therapy^*, RTx	Positive
17	M	46	Liver, bone	Sporadic	Surgery, sorafenib	Unknown
18	M	55	LN, lung, bone, soft tissue	Sporadic	Surgery, RTx	Positive

↵* Initially classified as differentiated thyroid carcinoma.
LN = lymph node; CTx = chemotherapy; TACE = transarterial chemoembolization; RTx = radiation therapy.